secwatch.observer — SEC 8-K summary
======================================

Issuer:     GALECTIN THERAPEUTICS INC (GALT)
CIK:        0001133416
Form:       8-K
Filed at:   2025-12-19T23:59:59+00:00
Accession:  0001140361-25-046115
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galectin Therapeutics receives FDA alignment on belapectin trial design; secures $10M credit line
--------------------------------------------------------------------------------

- FDA written response on belapectin shows alignment on patient population for registration trial; follow-up Type C meeting planned.
- Follow-up meeting to finalize trial design and present biomarker data from AASLD meeting not included in prior submission.
- Entered $10M unsecured, convertible line of credit from chairman Richard E. Uihlein; maturity extended to June 30, 2027.
- Existing credit facilities also extended; company expects funding through at least March 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133416/000114036125046115/0001140361-25-046115-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133416/000114036125046115/ef20061484_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-046115

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer